Interaction Checker

Interacciones de Alosetrón

Alosetrón (Lotronex) tiene 88 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 11; moderadas: 42; leves: 3; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 32. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Qué aspecto tiene Alosetrón

Todas las versiones (6)
Alosetrón, tableta de 1 mg: azul, ovalada, 11 mm, con la inscripción GX en una cara y CT1 en la otra.
GX / CT1
1 mg · azul · ovalada · 11 mm
Sebela
Alosetrón, tableta de 0.5 mg: blanca, ovalada, 11 mm, con la inscripción GX en una cara y EX1 en la otra.
GX / EX1
0.5 mg · blanca · ovalada · 11 mm
Sebela
Alosetrón, tableta de 0.5 mg: blanca, ovalada, 11 mm, con la inscripción AN248.
AN248
0.5 mg · blanca · ovalada · 11 mm
Amneal
Alosetrón, tableta de 1 mg: azul, ovalada, 11 mm, con la inscripción AN249.
AN249
1 mg · azul · ovalada · 11 mm
Amneal

Representaciones generadas a partir de los listados de productos de las etiquetas de la FDA: color, forma, tamaño e inscripción. 6 versiones documentadas de 6 etiquetadores.

Interacciones según la etiqueta

Interacciones graves (11)

  • Cannabidiol (con receta)anticonvulsivoGrave

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (etiqueta de Alosetrón, Contraindicaciones)

  • Cimetidinaantagonista H2Grave

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (etiqueta de Alosetrón, Contraindicaciones)

  • CiprofloxacinofluoroquinolonaGrave

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (etiqueta de Alosetrón, Contraindicaciones)

  • Deferasiroxsuplemento de hierroGrave

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (etiqueta de Alosetrón, Contraindicaciones)

  • FluvoxaminaISRSGrave

    Concomitant use of fluvoxamine ( 4.3 ) (etiqueta de Alosetrón, Contraindicaciones)

  • LevofloxacinofluoroquinolonaGrave

    Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • MexiletinaantiarrítmicoGrave

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (etiqueta de Alosetrón, Contraindicaciones)

  • MoxifloxacinofluoroquinolonaGrave

    Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • OfloxacinofluoroquinolonaGrave

    Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Viloxazinainhibidor de la recaptación de noradrenalinaGrave

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (etiqueta de Alosetrón, Contraindicaciones)

  • Zileutóninhibidor de CYP1A2Grave

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (etiqueta de Alosetrón, Contraindicaciones)

Interacciones moderadas (42)

  • AmiodaronaantiarrítmicoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Aprepitantinhibidor de CYP3A4Moderada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • AtazanavirantirretroviralModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • CiclosporinainmunosupresorModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • DarunavirantirretroviralModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Darunavir y cobicistatantirretroviralModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Diltiazembloqueador de los canales de calcioModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • DronedaronaantiarrítmicoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • EfavirenzantirretroviralModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Efavirenz, lamivudina y tenofovirantirretroviralModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • EluxadolinaopioideModerada

    Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. (etiqueta de Eluxadolina, Interacciones medicamentosas)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Eritromicinaantibiótico macrólidoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • EverolimusinmunosupresorModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Fluconazolantifúngico azólicoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • FosamprenavirantirretroviralModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Fosaprepitantinhibidor de CYP3A4Moderada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Imatinibinhibidor de CYP3A4Moderada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • IsoniazidaantibióticoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Itraconazolantifúngico azólicoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Ivacaftorinhibidor de CYP3A4Moderada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Ketoconazolantifúngico azólicoModerada

    Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • LeflunomidainmunosupresorModerada

    In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (etiqueta de Leflunomida, Interacciones medicamentosas)

  • LenacapavirantirretroviralModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Mifepristonainhibidor de CYP3A4Moderada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Mirabegrónagonista beta-adrenérgicoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • NefazodonaantidepresivoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Nirmatrelvir y ritonavirantiviralModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Palbociclibinhibidor de CYP3A4Moderada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • PerampanelanticonvulsivoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Posaconazolantifúngico azólicoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • PrimaquinaantipalúdicoModerada

    Effects of Primaquine on the Pharmacokinetics of Other Drugs CYP1A2 Substrates Published clinical and non-clinical reports indicate primaquine inhibits CYP1A2 enzyme activity and thus may lead to increased exposure of CYP1A2 substrate drugs (e.g., duloxetine, alosetron, theophylline and tizanidine) when co-administered with Primaquine phosphate Tablets. (etiqueta de Primaquina, Interacciones medicamentosas)

  • Ranolazinafármaco que prolonga el intervalo QTModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • RitonavirantirretroviralModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Suvorexantsedante-hipnóticoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • TeriflunomidainmunosupresorModerada

    In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (etiqueta de Teriflunomida, Interacciones medicamentosas)

  • Ticagrelorantiagregante plaquetarioModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Voriconazolantifúngico azólicoModerada

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (etiqueta de Alosetrón, Interacciones medicamentosas)

Menciones leves (3)

  • Dinitrato de isosorbida e hidralazinanitratoLeve

    Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • HidralazinavasodilatadorLeve

    Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • ProcainamidaantiarrítmicoLeve

    Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (etiqueta de Alosetrón, Interacciones medicamentosas)

Sin interacción significativa según la etiqueta (32)

  • Alopurinolinhibidor de la xantina oxidasaSin interacción

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • AminofilinametilxantinaSin interacción

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Butalbital, ácido acetilsalicílico y cafeínabarbitúricoSin interacción

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Butalbital, ácido acetilsalicílico, cafeína y codeínabarbitúricoSin interacción

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Butalbital, paracetamol y cafeínabarbitúricoSin interacción

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Butalbital, paracetamol, cafeína y codeínabarbitúricoSin interacción

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Desogestrel y etinilestradiolanticonceptivo oralSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Diacetato de etinodiol y etinilestradiolanticonceptivo oralSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Drospirenona y etinilestradiolanticonceptivo oralSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Ergotamina y cafeínaalcaloide ergóticoSin interacción

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • EstradiolestrógenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Estradiol y dienogestanticonceptivo oralSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Estradiol y noretisteronaestrógenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Estrógenos conjugadosestrógenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Estrógenos conjugados y bazedoxifenoestrógenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Estrógenos esterificados y metiltestosteronaestrógenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Etonogestrel y etinilestradiolestrógenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Febuxostatinhibidor de la xantina oxidasaSin interacción

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • FulvestrantestrógenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • LevonorgestrelprogestágenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Levonorgestrel y etinilestradiolanticonceptivo oralSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • MedroxiprogesteronaprogestágenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • MegestrolprogestágenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Norelgestromina y etinilestradiolestrógenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • NoretisteronaprogestágenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Noretisterona y etinilestradiolanticonceptivo oralSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Norgestimato y etinilestradiolanticonceptivo oralSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Norgestrel y etinilestradiolanticonceptivo oralSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • Orfenadrina, ácido acetilsalicílico y cafeínarelajante muscularSin interacción

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • PentoxifilinametilxantinaSin interacción

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (etiqueta de Alosetrón, Interacciones medicamentosas)

  • ProgesteronaprogestágenoSin interacción

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (etiqueta de Alosetrón, Interacciones medicamentosas)

  • TeofilinametilxantinaSin interacción

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (etiqueta de Alosetrón, Interacciones medicamentosas)

Compruebe Alosetrón frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.